Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

2008 • 25,031 citations

Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma

2007 • 5,572 citations

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

2015 • 5,267 citations

Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial

2010 • 2,417 citations

Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study

2009 • 1,957 citations

Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma

2013 • 1,792 citations

Survival and Prognostic Stratification of 670 Patients With Advanced Renal Cell Carcinoma

1999 • 1,782 citations

Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene

2003 • 1,276 citations

Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth

2011 • 1,162 citations

Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma

2015 • 1,120 citations

Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial

2016 • 857 citations

Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma

2015 • 356 citations

Direct regulation of GAS6/AXL signaling by HIF promotes renal metastasis through SRC and MET

2014 • 245 citations

Impact of Bone and Liver Metastases on Patients with Renal Cell Carcinoma Treated with Targeted Therapy

2013 • 233 citations

Kidney Cancer, Version 3.2015

2015 • 215 citations

Targeted Therapies for Renal Cell Carcinoma: Review of Adverse Event Management Strategies

2012 • 202 citations

c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma

2012 • 170 citations

Dual effects of a targeted small-molecule inhibitor (cabozantinib) on immune-mediated killing of tumor cells and immune tumor microenvironment permissiveness when combined with a cancer vaccine

2014 • 169 citations

Differential Expression of Axl and Gas6 in Renal Cell Carcinoma Reflecting Tumor Advancement and Survival

2009 • 144 citations

Kinase requirements in human cells: III. Altered kinase requirements inVHL−/− cancer cells detected in a pilot synthetic lethal screen

2008 • 138 citations

Negative impact of bone metastasis on outcome in clear-cell renal cell carcinoma treated with sunitinib

2010 • 137 citations

Prognostic factors for survival in 1059 patients treated with sunitinib for metastatic renal cell carcinoma

2013 • 128 citations

Combination Strategy Targeting VEGF and HGF/c-met in Human Renal Cell Carcinoma Models

2014 • 89 citations

Checkpoint inhibitors and other novel immunotherapies for advanced renal cell carcinoma

2016 • 87 citations

First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDC

2014 • 69 citations

Axl receptor tyrosine kinase is a potential therapeutic target in renal cell carcinoma

2015 • 61 citations

Contemporary treatment of metastatic renal cell carcinoma

2016 • 41 citations

Prescribing Preferences in the First-Line Treatment for Patients With Metastatic Renal Cell Carcinoma in the United States

2016 • 4 citations